|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jeanne Haggerty |
Date | 4/20/2021 12:23:13 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Climate Change
---FY 2022 Appropriations
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
Funding for the USDA
---H.R.1319: American Rescue Plan Act of 2021
------Funding the monitoring of COVID-19 in animals
------Supporting Farmers and Strengthening the Food Supply Chain
------Ensuring Equity for Farmers of Color Amid the Pandemic
---S.278: Emergency Relief for Farmers of Color Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
Genetically Engineered (GE) Animals
---H.R.133: Consolidated Appropriations Act for FY 2021
------GE Salmon
---H.R.1319: American Rescue Plan Act of 2021
------Funding the monitoring of COVID-19 in animals
------Supporting Farmers and Strengthening the Food Supply Chain
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------Feed Additives
------GE Salmon
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---International Consistency of Regulation for Gene Edited Products
---Labeling
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Genetically Engineered (GE) Plants
---Climate Issues & impact on the agriculture, food, and forestry sectors
---EPA Regulatory Approach to Gene Editing
---EPA proposed revisions to regulations related to the oversight of certain plant-incorporated protectants (PIPs)
---FDA Proposed Guidance on Gene Editing
---International Consistency of Regulation for Gene Edited Products
Review and Labeling of Food Derived from Biotechnology
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Regulatory Treatment of Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Food & Drug Administration (FDA), White House Office, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Matthew |
O'Mara |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---H.R.133: Consolidated Appropriations Act for FY 2021
------GE Salmon
---H.R.1319: American Rescue Plan Act of 2021
------Funding the monitoring of COVID-19 in animals
------Supporting Farmers and Strengthening the Food Supply Chain
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------Feed Additives
------GE Salmon
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---International Consistency of Regulation for Gene Edited Products
---Labeling
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived from Biotechnology
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, Environmental Protection Agency (EPA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Erick |
Lutt |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Coronavirus (COVID-19) Pandemic
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
------Ensuring Equity for Farmers of Color Amid the Pandemic
------Funding Allocation from HHS to BARDA for Therapeutics
------Funding for Vaccine Distribution
------Funding for Vaccine Hesitancy
------Funding the monitoring of COVID-19 in animals
------Supporting Farmers and Strengthening the Food Supply Chain
--- Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (Discussion Drafts)
--- Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biofuels
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for Biomass Crop Assistance Program
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for Biorefineries
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for FDA
---FY 2022 Appropriations
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities
Funding for Health Resources and Services Administration (HRSA) - 340B Program Integrity Issues
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
Funding for Health Resources and Services Administration (HRSA) - Countermeasures Injury Compensation Program (CICP)
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP)
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Appropriations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2022 Appropriations
Funding for the USDA
---H.R.1319: American Rescue Plan Act of 2021
------Funding the monitoring of COVID-19 in animals
------Supporting Farmers and Strengthening the Food Supply Chain
------Ensuring Equity for Farmers of Color Amid the Pandemic
---S.278: Emergency Relief for Farmers of Color Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA), Office of Management & Budget (OMB), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Appropriations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Investment Tax Credit
---Production Tax Credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Antitrust Legislation
---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021
Bayh-Dole Act/Tech Transfer
---FY 2022 Appropriations
---Bayh-Dole 40th Anniversary
---Follow Up Discussions about State Attorney General Letter
---March-In Rights
---NIST Proposed Rulemaking on Bayh-Dole
Compulsory Licensing
---Prescription Drug Price Relief Act (Discussion Drafts)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---We Protect American Investment in Drugs Act (Discussion Draft)
Coronavirus (COVID-19) Pandemic
---Bringing Back American Jobs Through Intellectual Property Repatriation Act (Discussion Draft House)
---Restrictions on Intellectual Property Rights
Diversity in Patenting
---Implementation of Study of Underrepresented Classes Chasing Engineering and Science Success (SUCCESS) Act of 2018
---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021
Drug Patenting
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---Affordable Prescriptions for Patients Act (Discussion Draft)
---Lower Costs, More Cures Act (Discussion Draft)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---Restrictions on Intellectual Property Rights
Intellectual Property Enforcement
---China
---India
---TRIPS Waiver
Inter Partes Review
---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft)
United States-Mexico-Canada Agreement (USMCA)
---Implementation of USMCA
US-China Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Natl Institute of Standards & Technology (NIST), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
Climate Change
---FY 2022 Appropriations
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
Funding for Biofuels
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for Biomass Crop Assistance Program
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for Biorefineries
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Renewable Fuel Standard (RFS)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Economic Hardship Waiver of the Renewable Volume Obligations (RVO) for 2020
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---H.R.133: Consolidated Appropriations Act for FY 2021
------GE Salmon
---H.R.1319: American Rescue Plan Act of 2021
------Funding the monitoring of COVID-19 in animals
------Supporting Farmers and Strengthening the Food Supply Chain
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------Feed Additives
------GE Salmon
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---FDA Regulatory Approach to Animal Biotechnology
---International Consistency of Regulation for Gene Edited Products
---Labeling
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived from Biotechnology
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office, Environmental Protection Agency (EPA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Erick |
Lutt |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
Biorefineries (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
Climate Change
---FY 2022 Appropriations
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
Funding for Biofuels
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for Biomass Crop Assistance Program
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Funding for Biorefineries
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------USDA Energy Program Funding
---Climate Issues & impact on the agriculture, food, and forestry sectors
Renewable Fuel Standard (RFS)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.Con.Res.5: A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030
------Cruz Amdt. #871
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Economic Hardship Waiver of the Renewable Volume Obligations (RVO) for 2020
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee
340B Drug Discount Program
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
Antibiotic & Diagnostic Tax Credit
Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of Medical Countermeasure Innovation Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---National Biodefense Strategy
Biosimilars
---BSUFA
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
Coronavirus (COVID-19) Pandemic
---H.R.869/S.289: Research Investment to Spark the Economy (RISE) Act of 2021
---H.R.1319: American Rescue Plan Act of 2021
------Funding Allocation from HHS to BARDA for Therapeutics
------Funding for Vaccine Distribution
------Funding for Vaccine Hesitancy
---DISARM Act (Discussion Draft)
---COVID-19 Lessons Learned
---COVID-19 Pricing-Related Provisions
---COVID-19 Vaccine Distribution
---Defense Production Act (DPA)
---Drug Supply Chain Management
---Healthcare Disparities
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---In-Home Administration of Part B Drugs
---Medicare Reimbursement Policies
---Monoclonal Antibody Coverage and Utilization
---Patient Cost-Sharing and Smoothing
---R&D Funding for Medical Countermeasures
---Restrictions on Intellectual Property Rights
---Small Business Loans
---Temporarily Refundable R&D Credit
Diagnostics and Personalized Medicine Regulation and Oversight
---VALID Act (Discussion Draft)
Diversity & Inclusion
---H.R.1319: American Rescue Plan Act of 2021
---Clinical Trial Diversity
Drug Evaluation and Review
---COVID-19 Lessons Learned
---Expedited Pathways
---FDA Hiring Flexibility
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Innovation Incentives
---Prescription Drug User Fee Act (PDUFA) VII Priorities
---Use of Real-World Evidence
Drug Importation
---S.920: A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.
Drug Manufacturing, Quality & Distribution
---H.R.1319: American Rescue Plan Act of 2021
------Funding for Vaccine Distribution
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
---Drug Shortages
---Executive Order on Buy American
---Supply Chain Integrity and Traceability
Drug Patenting
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---Affordable Prescriptions for Patients Act (Discussion Draft)
---Lower Costs, More Cures Act (Discussion Draft)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---Restrictions on Intellectual Property Rights
Drug Pricing
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---S.908: A bill to amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
---S.909: A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
---Lower Costs, More Cures Act (Discussion Draft)
---Lower Drug Costs Now Act (Discussion Draft)
---Medicare Prescription Drug Price Negotiation Act (Discussion Drafts)
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Drug Pricing Provisions
---Reference Pricing in Drug Reimbursement
Funding for Antimicrobial Resistance Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (Discussion Draft)
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for FDA
---FY 2022 Appropriations
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities
Funding for Health Resources and Services Administration (HRSA) - 340B Program Integrity Issues
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
Funding for Health Resources and Services Administration (HRSA) - Countermeasures Injury Compensation Program (CICP)
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
Funding for Health Resources and Services Administration (HRSA) - Vaccine Injury Compensation Program (VICP)
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the HHS Office of Infectious Disease and HIV/AIDS Policy
---FY 2022 Appropriations
Medicaid
---H.R.133: Consolidated Appropriations Act for FY 2021
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule
Opioid Crisis
---FDA Reforms
Orphan Drug Issues
---Tax Credit
Reimbursement and Coverage of Innovative Products
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---S.908: A bill to amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
---S.909: A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
---Lower Costs, More Cures Act (Discussion Draft)
---Lower Drug Costs Now Act (Discussion Draft)
---Administration Rebate Rule
---CMMI Authority
---Drug Pricing Provisions
---Medicare Part B Physician-Administered Products
---Protected Classes
---Reference Pricing in Drug Reimbursement
---Value-Based Purchasing (VBP) Rule
Vaccines and Infectious Diseases
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
------Funding for Vaccine Distribution
------Funding for Vaccine Hesitancy
---DISARM Act (Discussion Draft)
---Protecting Seniors through Immunizations Act (Discussion Draft)
---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (Discussion Drafts)
---Adult Immunization
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Monoclonal Antibody Coverage and Utilization
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety
---Vaccine and Antimicrobial Resistance Product Development and Incentives
Vaccine Injury Compensation Program Tax
---FY 2022 Appropriations
---Vaccine Access Improvement Act (Discussion Draft)
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Aiken |
Hackett |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Claire |
Brandewie |
|
|
|
Cartier |
Esham |
|
|
|
Camelia |
Thompson |
|
|
|
Danielle |
Friend |
|
|
|
Hans |
Sauer |
|
|
|
John |
Murphy |
|
|
|
Joseph |
Damond |
|
|
|
Phyllis |
Arthur |
|
|
|
Jamie |
Gregorian |
|
|
|
Joel |
Straus |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of Medical Countermeasure Innovation Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---National Biodefense Strategy
Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (Discussion Drafts)
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Phyllis |
Arthur |
|
|
|
Aiken |
Hackett |
|
|
|
Claire |
Brandewie |
|
|
|
Jamie |
Gregorian |
|
|
|
Joel |
Straus |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---Implementation of Medical Countermeasure Innovation Act of 2016
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---National Biodefense Strategy
Coronavirus (COVID-19) Pandemic
---H.R.1319: American Rescue Plan Act of 2021
------Funding Allocation from HHS to BARDA for Therapeutics
------Funding for Vaccine Distribution
------Funding for Vaccine Hesitancy
---Temporarily Refundable R&D Credit
Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (Discussion Drafts)
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
|
Phyllis |
Arthur |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
|
Joel |
Straus |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
21st Century Cures Act 2.0
---RFI from House Energy and Commerce Committee
Coronavirus (COVID-19) Pandemic
---DISARM Act (Discussion Draft)
---COVID-19 Pricing-Related Provisions
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---In-Home Administration of Part B Drugs
---Patient Cost-Sharing and Smoothing
Drug Pricing
---H.R.133: Consolidated Appropriations Act for FY 2021
---S.908: A bill to amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
---S.909: A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
---Lower Costs, More Cures Act (Discussion Draft)
---Lower Drug Costs Now Act (Discussion Draft)
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Drug Pricing Provisions
---Reference Pricing in Drug Reimbursement
Medicaid
---H.R.133: Consolidated Appropriations Act for FY 2021
---Alternative payment arrangements for gene therapies
---Average Manufacturer Price Calculations
---Drug Benefit Design
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule
Reimbursement and Coverage of Innovative Products
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---S.908: A bill to amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes.
---S.909: A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
---Lower Costs, More Cures Act (Discussion Draft)
---Lower Drug Costs Now Act (Discussion Draft)
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---Administration Rebate Rule
---CMMI Authority
---Drug Pricing Provisions
---Medicare Part B Physician-Administered Products
---Protected Classes
---Reference Pricing in Drug Reimbursement
---Value-Based Purchasing (VBP) Rule
Vaccines and Infectious Diseases
---S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---Protecting Seniors through Immunizations Act (Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Claire |
Brandewie |
|
|
|
Aiken |
Hackett |
|
|
|
Jamie |
Gregorian |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Incentives
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---American Innovation Act (Discussion Drafts)
---IGNITE American Innovation Act (Discussion Drafts)
---Infectious Disease Therapies Research and Innovation Act (Discussion Draft)
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
---Reform of Net Operating Loss Rules
Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---Market Liquidity Proposals
CARES Act Payroll Protection Loan Program
Coronavirus (COVID-19) Pandemic
---Coronavirus Emerging Growth Companies (EGC) Extension Act (Discussion Draft)
---IGNITE American Innovation Act (Discussion Drafts)
---Small Business Loans
---Temporarily Refundable R&D Credit
Coronavirus (COVID-19) Small Business Loans (Non-Funding)
---Affiliation
---Eligibility
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Payroll Tax Deferral
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
Proxy Advisory Services
---Impact of Policies on Small Public Companies
Reform of SEC Regulation D
---Accredited Investor Certification
Sarbanes Oxley Section 404 (b)
---Fostering Innovation Act (Discussion Draft)
---Small Issuer Exemption
Short Selling Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Cameron |
Arterton |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
|
Cartier |
Esham |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Antibiotic & Diagnostic Tax Credit
Biofuels (Non-Funding)
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---Incentives for Sustainable Aviation Fuels
---Sustainable Aviation Fuels Tax Credit
Capital Formation Incentives
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---American Innovation Act (Discussion Drafts)
---IGNITE American Innovation Act (Discussion Drafts)
---Infectious Disease Therapies Research and Innovation Act (Discussion Draft)
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
---Reform of Net Operating Loss Rules
Coronavirus (COVID-19) Pandemic
---Bringing Back American Jobs Through Intellectual Property Repatriation Act (Discussion Draft House)
---Coronavirus Emerging Growth Companies (EGC) Extension Act (Discussion Draft)
---IGNITE American Innovation Act (Discussion Drafts)
---Temporarily Refundable R&D Credit
Orphan Drug Issues
---Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---Investment Tax Credit
---Production Tax Credit
Research & Development Tax Credit Reforms
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
---American Innovation and Competitiveness Act (AICA) (Discussion Draft)
---Expensing of R&D Expenditures
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---R&D Payroll Credit
Vaccine Injury Compensation Program Tax
---Vaccine Access Improvement Act (Discussion Draft)
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cameron |
Arteron |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
|
Shea |
Hartley |
|
|
|
David |
Lachmann |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Digital Trade
---EU Digital Strategy
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
Genetically Engineered (GE) Animals
---International Consistency of Regulation for Gene Edited Products
Genetically Engineered (GE) Plants
---International Consistency of Regulation for Gene Edited Products
Intellectual Property International Enforcement
---China
---Mexico
---TRIPS Waiver
The United States-Mexico-Canada Agreement (USMCA)
---Ag-Biotech Provisions
---Implementation of United States-Mexico-Canada Agreement (USMCA)
---Mexico Draft Decree Banning Genetically Modified Corn
US-China Trade Agreement
---Ag-Biotech Provisions
---IP Provisions
US-EU Trade Agreement
---Ag-Biotech Provisions
World Trade Organization
---E-Commerce Negotiations
---TRIPS Waiver
World Health Organization (WHO)
---United States Withdrawal from the World Health Organization (WHO)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Patent & Trademark Office (PTO), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Erick |
Lutt |
|
|
|
Matthew |
O'Mara |
|
|
|
Joseph |
Damond |
|
|
|
Hans |
Sauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |